Neutralizing antibodies are important for immunity against SARS-CoV-2 and as therapeutics
for the prevention and treatment of COVID-19. Here, we identified high-affinity nanobodies …

Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to
reduce the burden placed on health systems, the situation remains critical. Effective …

Interventions against variants of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) are urgently needed. Stable and potent nanobodies (Nbs) that target the receptor …

Antibodies binding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
spike have therapeutic promise, but emerging variants show the potential for virus escape …

Without an effective prophylactic solution, infections from SARS-CoV-2 continue to rise
worldwide with devastating health and economic costs. SARS-CoV-2 gains entry into host …

Since the start of the COVID-19 pandemic, SARS-CoV-2 has caused millions of deaths
worldwide. Although a number of vaccines have been deployed, the continual evolution of …

Cost-effective, efficacious therapeutics are urgently needed to combat the COVID-19
pandemic. In this study, we used camelid immunization and proteomics to identify a large …

The dramatically expanding coronavirus disease 2019 (COVID-19) needs multiple effective
countermeasures. Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for …

The emergence of SARS-CoV-2 variants threatens current vaccines and therapeutic
antibodies and urgently demands powerful new therapeutics that can resist viral escape. We …

Cellular entry of SARS-CoV-2 requires the binding between the receptor-binding domain
(RBD) of the viral Spike protein and the cellular angiotensin-converting enzyme 2 (ACE2) …